Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.

The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.

Inclusion Criteria:

• Participant successfully completes 96 weeks of treatment in Study 4658-102.

Exclusion Criteria:

• Participant has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the participant, or make it unlikely that the course of treatment or follow-up would be completed, or impair the assessment of study results.

Other inclusion/exclusion criteria apply.

There are agreements between the Principal Investigators and the Sponsor (or its agents) that restrict the PIs rights to discuss or publish trial results after the trial is completed.